Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aerovate Therapeutics, Inc.

2.51
-0.0100-0.40%
Post-market: 2.510.00000.00%16:41 EDT
Volume:199.68K
Turnover:503.68K
Market Cap:72.75M
PE:-1.03
High:2.56
Open:2.56
Low:2.50
Close:2.52
Loading ...

Company Profile

Company Name:
Aerovate Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
30
Office Location:
930 Winter Street,Suite M-500,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Timothy P. Noyes
Chief Executive Officer and Director
Mark Iwicki
Chairperson and Director
David Grayzel
Director
Joshua Resnick
Director
Maha Katabi
Director

Shareholders

Name
Position
Timothy P. Noyes
Chief Executive Officer and Director
Benjamin T. Dake
President, Chief Operating Officer and Secretary
George A. Eldridge
Chief Financial Officer and Treasurer
Hunter Gillies
Chief Medical Officer
Ralph Niven
Chief Development Officer